Royce & Associates LP Sells 207,785 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Royce & Associates LP cut its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 17.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,004,501 shares of the medical technology company's stock after selling 207,785 shares during the quarter. Royce & Associates LP owned about 0.71% of Alphatec worth $9,221,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Alphatec by 11.3% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company's stock valued at $16,280,000 after buying an additional 297,850 shares during the period. Barclays PLC increased its holdings in Alphatec by 362.3% in the 3rd quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock valued at $948,000 after buying an additional 133,653 shares during the period. Franklin Resources Inc. increased its holdings in Alphatec by 299.3% in the 3rd quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company's stock valued at $343,000 after buying an additional 48,308 shares during the period. State Street Corp lifted its holdings in shares of Alphatec by 10.1% during the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company's stock worth $17,453,000 after acquiring an additional 287,350 shares during the period. Finally, Congress Asset Management Co. boosted its position in shares of Alphatec by 235.4% during the 4th quarter. Congress Asset Management Co. now owns 434,966 shares of the medical technology company's stock valued at $3,993,000 after acquiring an additional 305,296 shares in the last quarter. Institutional investors and hedge funds own 66.35% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Piper Sandler raised their target price on Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and set a $16.00 price target on shares of Alphatec in a report on Thursday, February 27th. StockNews.com raised Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. Barclays boosted their price objective on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 22nd. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $17.67.

Alphatec Trading Down 2.6 %

Shares of ATEC traded down $0.27 during trading hours on Friday, reaching $9.93. The stock had a trading volume of 1,751,219 shares, compared to its average volume of 1,974,522. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $14.54. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The company has a market cap of $1.43 billion, a P/E ratio of -7.76 and a beta of 1.39. The firm has a 50-day moving average of $10.96 and a 200 day moving average of $8.83.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The company had revenue of $176.79 million for the quarter, compared to analyst estimates of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. On average, sell-side analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Insider Transactions at Alphatec

In other news, CEO Patrick Miles sold 12,691 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $10.64, for a total transaction of $135,032.24. Following the completion of the sale, the chief executive officer now owns 5,857,603 shares in the company, valued at $62,324,895.92. The trade was a 0.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP David Sponsel sold 58,283 shares of Alphatec stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $10.71, for a total value of $624,210.93. Following the sale, the executive vice president now directly owns 502,311 shares of the company's stock, valued at approximately $5,379,750.81. The trade was a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 337,321 shares of company stock worth $3,828,060 in the last three months. Insiders own 22.80% of the company's stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.